NASDAQ
11.83USD
-0.09 (-0.76%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
994M
P/E
—
EPS
—
Beta
0.87
52W range
1.5-12.6
Day range
11.51–12.33
Open
11.96
Prev close
11.92
Volume
2.8M
Avg volume
6.4M
Dividend
0.00
IPO
2018-07-20
https://www.globenewswire.com/news-release/2026/08/05/3339850/0/en/Bragar-Eagel-Squire-P-C-is-Investigating-Replimune-Group-Inc-on-Behalf-of-Replimune-Stockholders-and-Encourages-Investors-to-Contact-the-Firm.html · 8/5/2026-0.80
https://www.businesswire.com/news/home/20260728108840/en/Securities-Fraud-Investigation-Into-Replimune-Group-Inc.-REPL-Announced-%E2%80%93-Shareholders-Who-Lost-Money-Urged-To-Contact-The-Law-Offices-of-Frank-R.-Cruz/ · 7/29/2026-0.80
https://www.proactiveinvestors.com/companies/news/1096158 · 7/28/2026-1.00
https://www.globenewswire.com/news-release/2026/05/31/3303918/0/en/Replimune-Presents-Final-First-in-Human-Data-for-RP2-in-Advanced-Solid-Tumors-During-Oral-Presentation-at-the-2026-American-Society-of-Clinical-Oncology-Annual-Meeting.html · 5/31/2026
https://www.globenewswire.com/news-release/2026/05/18/3296275/0/en/TRDA-Investors-Have-Opportunity-to-Join-Entrada-Therapeutics-Inc-Fraud-Investigation-with-the-Schall-Law-Firm.html · 5/18/2026-0.80
https://www.globenewswire.com/news-release/2026/05/18/3296274/0/en/REPL-Investors-Have-Opportunity-to-Join-Replimune-Group-Inc-Fraud-Investigation-with-the-Schall-Law-Firm.html · 5/18/2026-1.00
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-replimune-group-inc---repl-302773020.html · 5/15/2026-1.00
https://www.cnbc.com/2026/05/12/trump-fda-commissioner-marty-makary-out.html · 5/12/2026-0.60
https://www.proactiveinvestors.com/companies/news/1090443 · 4/13/2026-1.00
https://www.globenewswire.com/news-release/2026/04/13/3272411/0/en/EquipmentShare-Inc-Shareholders-Are-Encouraged-to-Reach-Out-to-Johnson-Fistel-for-More-Information-About-Potentially-Recovering-Their-Losses.html · 4/13/2026-0.60
https://www.zacks.com/stock/news/2811014/here-s-why-replimune-stock-skyrockets-nearly-131-in-3-months?cid=CS-STOCKNEWSAPI-FT-analyst_blog|price_surge_/_plunge-2811014 · 12/31/2025+0.80
https://www.defenseworld.net/2025/11/22/replimune-group-inc-nasdaqrepl-given-average-recommendation-of-moderate-buy-by-brokerages.html · 11/22/2025+0.60
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
